Log In | Register
WASHINGTON — Barely a week after the Food and Drug Administration cleared the way for a second anti-wrinkle drug, the maker of Botox is defending its product, warning physicians about the risks of switching between the two drugs.
Allergan has good reason to defend Botox: it accounts for nearly one-third of the company's sales.
Company CEO David Pyott tells The Associated Press his drug's head-start in the U.S. will keep sales strong. He also brushes off speculation that his company is an acquisition target.
As competitor Medicis Pharmaceutical Corp. prepares to roll out its drug Dysport, analysts expect a full-scale marketing battle from the two leading cosmetic product companies.
© 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
